ClinicalTrials.Veeva

Menu
A

AZ Delta | Clinical Trial Center - Pneumology

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3298176
Tirzepatide
BAY2927088
Selpercatinib
Luspatercept
Pirtobrutinib
Alimta
Magrolimab
Pembrolizumab
Venetoclax

Parent organization

This site is a part of AZ Delta vzw

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 18 total trials

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The main purpose of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with relapsed or refractory chr...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: Placebo
Drug: Selpercatinib

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advan...

Enrolling
Gastroesophageal Cancer
Drug: Rescue medication
Drug: Supportive care measures

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called hu...

Enrolling
HER2 Mutation
Advanced Non-small Cell Lung Cancer
Drug: Cisplatin
Drug: Pembrolizumab

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative ne...

Active, not recruiting
Anemia
Myelofibrosis
Other: Placebo
Drug: ACE-536

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants wit...

Active, not recruiting
Colorectal Cancer
Biological: MK-4830
Biological: Pembrolizumab/Quavonlimab

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spre...

Active, not recruiting
EGFR Mutation
HER2 Mutation
Drug: BAY2927088_formulation A
Drug: BAY2927088_formulation B_2

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tu...

Enrolling
Carcinoma, Hepatocellular
Biliary Tract Neoplasms
Drug: Pembrolizumab
Drug: Lenvatinib

PDC-LUNG-101 trial is an open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary...

Active, not recruiting
Non Small Cell Lung Cancer
Biological: PDC*lung01
Drug: Alimta Injectable Product

Trial sponsors

Lilly logo
Merck Sharp & Dohme (MSD) logo
Abbott logo
Bayer logo
Loxo Oncology logo
Celgene logo
D
Gilead Sciences logo
Janssen (J&J Innovative Medicine) logo
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems